UBS AM’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
UBS AM's CTNM Position: Q3 2026 in Review
UBS AM opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 275 shares worth $3.69K. The stake represents ﹤0.01% of the portfolio and ranks #3966 among its holdings.
86 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- UBS AM held 275 shares of Contineum Therapeutics worth $3.69K as of Q3 2026.
- Contineum Therapeutics was a new UBS AM position in Q3 2026.
- Contineum Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3966 holding.
- 86 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.